FDA Warns of Risk for Delayed-onset Inflammation Near Dermal Filler Sites

July 13, 2023
Injection of facial filler

The US Food and Drug Administration updated its informational webpage on dermal fillers to reflect the risk of delayed-onset inflammation near dermal filler treatment sites.

The webpage now includes mention of delayed-onset inflammation near the dermal filler treatment site following viral or bacterial illnesses or infections, vaccinations, or dental procedures along with risk of bruising, redness, swelling, and pain.

Typically, the reported inflammation is responsive to treatment or resolves on its own. The FDA encourages consumers and patients to discuss all treatment options, including dermal filler procedures, with their health care provider to understand the benefits and risks associated with the use of these medical devices, the FDA notes.

Read more at Modern Aesthetics >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • South Carolina Medical Board Warns Against Use of Research-Grade Peptides
    • Lilly Sues Six Companies Over Alleged Sales of Experimental Weight-Loss Drug Retatrutide
    • DaySpark Becomes Silver Vendor Affiliate with the American Med Spa Association
    • Allergan Aesthetics Refreshes Allergan Partner Privileges to Better Support Today’s Modern Aesthetics Practices
    • Galderma Receives EU Approval for Restylane Shaype: Bone-Mimicking Hyaluronic Acid Injectable for Chin